Schrödinger, Inc. acquired Xtal BioStructures, Inc. for $7.4 million.
January 17, 2022
Share
Schrödinger, Inc. (NasdaqGS:SDGR) acquired Xtal BioStructures, Inc. for $6 million on January 14, 2022. The consideration consisted of an all-cash payment of $6 million. XTAL BioStructures is now operating as part of Schrödinger and Schrödinger will continue to operate XTAL BioStructures' services at the current location.
Schrödinger, Inc. (NasdaqGS:SDGR) completed the acquisition of Xtal BioStructures, Inc. for $7.4 million on January 14, 2022.
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.
SCHRÖDINGER, INC. 
